ArticlePloS one2026
Association between Red Cell Distribution Width (RDW)-related inflammatory biomarkers and prognosis in ICU Cirrhosis patients: Evidence from the MIMIC-IV.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCirrhosis signifies a critical phase in liver disease with high mortality, particularly in patients admitted to intensive care unit (ICU). Red cell distribution width (RDW) demonstrates prognostic value in various conditions, with evidence linking it to inflammation and adverse outcomes in liver disease. However, the predictive utility of RDW and its derived indices in patients with cirrhosis admitted to ICU remains undetermined. This study investigated the associations between RDW-related biomarkers and prognosis in critically ill cirrhosis patients.
methodsA retrospective analysis used data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database, including 1,871 adults with cirrhosis at first ICU admission. The analyzed biomarkers were RDW, RDW-to-albumin ratio (RAR), RDW-to-platelet ratio (RPR), and hemoglobin-to-RDW ratio (HRR). The primary outcome was 30-day all-cause mortality; secondary outcomes were 90-day, and 365-day mortality. Adjusted multivariate Cox regression models determined biomarker-mortality associations. Receiver operating characteristic (ROC) curve analyses evaluated predictive performance of the biomarkers.
resultsThe cohort had a mean age of 58.8 ± 12.3 years and 64.8% of the patients were male. The mortality rates were 31.8% (30-day), 39.3% (90-day), and 48.0% (365-day). Mortality was consistently higher in high versus low RDW groups. After multivariable adjustment, all biomarkers were independently associated with 30-day, 90-day, and 365-day mortality, respectively. When expressed per SD, RDW (HR 1.41, 95% CI 1.30-1.52), RAR (HR 1.17, 95% CI 1.11-1.24), RPR (HR 1.19, 95% CI 1.11-1.28), and HRR (HR 0.52, 95% CI 0.44-0.61) were each significantly associated with 30-day mortality. ROC analysis revealed RDW had the highest predictive value (AUC 63.3%), followed by HRR (AUC 61.7%), RAR (AUC 59.6%), and RPR (AUC 55.6%). RDW demonstrated the highest discriminative ability for 30-day mortality, with incremental predictive value when combined with established scores (absolute AUC increase 0.68-1.58%).
conclusionRDW-related biomarkers demonstrate statistically significant but modest associations with mortality in ICU cirrhosis patients. RDW and HRR showed the strongest predictive capabilities among the four indices, though standalone discrimination was limited. These accessible, cost-effective biomarkers may serve as adjunctive prognostic markers when combined with established scoring systems. However, further prospective validation is required before clinical implementation, and dynamic changes in these biomarkers warrant investigation in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.